A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
← catalyst calendarNCT06588686 · readout ≤ 282 d
Sponsored by Vicore Pharma AB (industry) · VICO.ST — their whole pipeline →. With Population Services International.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
378actual
Sites
104
Countries
Argentina, Australia, Austria +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-21
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-09 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
- Drug: Buloxibutid — also filed as C21
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTo evaluate the efficacy of buloxibutid compared to placebo in participants with IPF as assessed by FVC
measured week 52
Permalink · VICO.ST's whole pipeline · Catalyst calendar · Every registered study · What changed